India Pharma Outlook Team | Saturday, 21 June 2025
Following its prior report on the clinical success of Mounjaro, Eli Lilly has confirmed a considerable commercial response for the drug in India - the need for effective obesity and diabetes treatment is urgent in this rapidly growing market.
The US company that launched Mounjaro in India ahead of Novo Nordisk's Wegovy has registered sales of over 81,570 units valued at ?239.4 million ($2.76 million) as of May 2025 according to report by PharmaTrac.
Mounjaro, an injectable dual-action drug for Type 2 diabetes and obesity, had a growing demand of 60% between April and May, against a backdrop of India's prevailing metabolic health crisis, which includes nearly one in four adults being classified as overweight, obese, or a combination of both. The number of diabetes in India is projected to remain high and reach over 124 million by 2045.
Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment
Lilly has emphasized their desire to meet growing demand and provided evidence of over $50 billion investment worldwide since 2020 to increase their manufacturing capabilities. Lilly's pricing strategy, which represents a more affordable option in India, may contribute to positioning Mounjaro treatment for many.
As India becomes a key market in the global obesity drug race, domestic drugmakers are also accelerating efforts to produce cost-effective alternatives in a market projected to touch $150 billion by the early 2030s.
